LLY · 10-Q · 2026Q1 · Full report
Regulatory Compliance / Manufacturing Risk
ELI LILLY & Co · 2026-04-30 · Importance 58 · Surprise 42 · In source text
Lilly describes regulatory issues around compliance with current Good Manufacturing Practices, quality assurance, safety signals, evolving standards, and scrutiny of excipients and potential impurities (e.g., nitrosamines). The filing warns such issues can lead to regulatory and legal actions, product recalls and seizures, fines and penalties, production interruptions and shortages, import bans, inability to realize capital expenditures, or delays/denials of approvals or supplemental approvals. Any of these consequences could cause reputational harm and adversely affect the business. Lilly therefore flags manufacturing quality and regulatory compliance as material operational and regulatory risks.
Key facts
- We are engaged in litigation and investigations related to the 340B program, access to insulin, pricing, product safety, and other matters. source
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| liability | negative | contingent | — | We are engaged in litigation and investigations related to the 340B program, access to insulin, pricing, product safety, and other matters. |